Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators. Brose MS, et al. Among authors: molnar i. Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24. Lancet. 2014. PMID: 24768112 Free PMC article. Clinical Trial.
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA. Miller K, et al. Among authors: molnar i. BMC Cancer. 2016 Jun 3;16:352. doi: 10.1186/s12885-016-2385-z. BMC Cancer. 2016. PMID: 27259714 Free PMC article. Clinical Trial.
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD. Munster P, et al. Among authors: molnar i. Br J Cancer. 2018 Oct;119(9):1086-1093. doi: 10.1038/s41416-018-0235-2. Epub 2018 Oct 26. Br J Cancer. 2018. PMID: 30361524 Free PMC article. Clinical Trial.
Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.
Adiwijaya BS, Kim J, Lang I, Csõszi T, Cubillo A, Chen JS, Wong M, Park JO, Kim JS, Rau KM, Melichar B, Gallego JB, Fitzgerald J, Belanger B, Molnar I, Ma WW. Adiwijaya BS, et al. Among authors: molnar i. Clin Pharmacol Ther. 2017 Dec;102(6):997-1005. doi: 10.1002/cpt.720. Epub 2017 Jun 5. Clin Pharmacol Ther. 2017. PMID: 28445610 Free PMC article.
Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases.
Tökés AM, Szász AM, Geszti F, Lukács LV, Kenessey I, Turányi E, Meggyesházi N, Molnár IA, Fillinger J, Soltész I, Bálint K, Hanzély Z, Arató G, Szendröi M, Kulka J. Tökés AM, et al. Among authors: molnar ia. J Clin Pathol. 2015 Apr;68(4):274-82. doi: 10.1136/jclinpath-2014-202607. Epub 2015 Jan 16. J Clin Pathol. 2015. PMID: 25595275
Breast carcinoma subtypes show different patterns of metastatic behavior.
Molnár IA, Molnár BÁ, Vízkeleti L, Fekete K, Tamás J, Deák P, Szundi C, Székely B, Moldvay J, Vári-Kakas S, Szász MA, Ács B, Kulka J, Tőkés AM. Molnár IA, et al. Virchows Arch. 2017 Mar;470(3):275-283. doi: 10.1007/s00428-017-2065-7. Epub 2017 Jan 19. Virchows Arch. 2017. PMID: 28101678
400 results